124 related articles for article (PubMed ID: 34888692)
1. Cardiovascular burden in systemic sclerosis: QRISK3 versus Framingham for risk estimation.
Di Battista M; Barsotti S; Della Rossa A; Mosca M
Mod Rheumatol; 2022 Apr; 32(3):584-588. PubMed ID: 34888692
[TBL] [Abstract][Full Text] [Related]
2. Framingham, ACC/AHA or QRISK3: which is the best in systemic lupus erythematosus cardiovascular risk estimation?
Di Battista M; Tani C; Elefante E; Chimera D; Carli L; Ferro F; Stagnaro C; Mosca M
Clin Exp Rheumatol; 2020; 38(4):602-608. PubMed ID: 31694741
[TBL] [Abstract][Full Text] [Related]
3. Combined use of QRISK3 and SCORE2 increases identification of ankylosing spondylitis patients at high cardiovascular risk: Results from the CARMA Project cohort after 7.5 years of follow-up.
Polo Y la Borda J; Castañeda S; Sánchez-Alonso F; Plaza Z; García-Gómez C; Ferraz-Amaro I; Erausquin C; Valls-García R; Fábregas MD; Delgado-Frías E; Mas AJ; González-Juanatey C; Llorca J; González-Gay MA;
Semin Arthritis Rheum; 2024 Jun; 66():152442. PubMed ID: 38555727
[TBL] [Abstract][Full Text] [Related]
4. Assessing the validity of QRISK3 in predicting cardiovascular events in systemic lupus erythematosus.
Zhu L; Singh M; Lele S; Sahakian L; Grossman J; Hahn B; McMahon M
Lupus Sci Med; 2022 Feb; 9(1):. PubMed ID: 35193947
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Risk Factors and Atherosclerotic Cardiovascular Events Among Incident Cases of Systemic Sclerosis: Results From a Population-Based Cohort (1980-2016).
Kurmann RD; Sandhu AS; Crowson CS; Matteson EL; Osborn TG; Warrington KJ; Mankad R; Makol A
Mayo Clin Proc; 2020 Jul; 95(7):1369-1378. PubMed ID: 32622445
[TBL] [Abstract][Full Text] [Related]
6. Carotid plaques as predictors of cardiovascular events in patients with Rheumatoid Arthritis. Results from a 5-year-prospective follow-up study.
Corrales A; Vegas-Revenga N; Rueda-Gotor J; Portilla V; Atienza-Mateo B; Blanco R; Castañeda S; Ferraz-Amaro I; Llorca J; González-Gay MA
Semin Arthritis Rheum; 2020 Dec; 50(6):1333-1338. PubMed ID: 32416998
[TBL] [Abstract][Full Text] [Related]
7. QRISK3 improves detection of cardiovascular disease risk in patients with systemic lupus erythematosus.
Edwards N; Langford-Smith AWW; Parker BJ; Bruce IN; Reynolds JA; Alexander MY; McCarthy EM; Wilkinson FL
Lupus Sci Med; 2018; 5(1):e000272. PubMed ID: 30167314
[TBL] [Abstract][Full Text] [Related]
8. Prediction of Coronary Artery Disease and Major Adverse Cardiovascular Events Using Clinical and Genetic Risk Scores for Cardiovascular Risk Factors.
Ramírez J; van Duijvenboden S; Young WJ; Tinker A; Lambiase PD; Orini M; Munroe PB
Circ Genom Precis Med; 2022 Oct; 15(5):e003441. PubMed ID: 35861959
[TBL] [Abstract][Full Text] [Related]
9. Subclinical atherosclerosis in systemic sclerosis and rheumatoid arthritis: a comparative matched-cohort study.
Dimitroulas T; Baniotopoulos P; Pagkopoulou E; Soulaidopoulos S; Nightingale P; Sandoo A; Karagiannis A; Douglas K; Sachinidis A; Garyfallos A; Kitas G
Rheumatol Int; 2020 Dec; 40(12):1997-2004. PubMed ID: 32772133
[TBL] [Abstract][Full Text] [Related]
10. Assessment of QRISK3 as a predictor of cardiovascular disease events in type 2 diabetes mellitus.
Mu X; Wu A; Hu H; Zhou H; Yang M
Front Endocrinol (Lausanne); 2022; 13():1077632. PubMed ID: 36518244
[TBL] [Abstract][Full Text] [Related]
11. Circulating endothelial progenitor cells in systemic sclerosis: relation to impaired angiogenesis and cardiovascular manifestations.
Nevskaya T; Bykovskaia S; Lyssuk E; Shakhov I; Zaprjagaeva M; Mach E; Ananieva L; Guseva N; Nassonov E
Clin Exp Rheumatol; 2008; 26(3):421-9. PubMed ID: 18578963
[TBL] [Abstract][Full Text] [Related]
12. Use of risk chart algorithms for the identification of psoriatic arthritis patients at high risk for cardiovascular disease: findings derived from the project CARMA cohort after a 7.5-year follow-up period.
Polo Y La Borda J; Castañeda S; Heras-Recuero E; Sánchez-Alonso F; Plaza Z; García Gómez C; Ferraz-Amaro I; Sanchez-Costa JT; Sánchez-González OC; Turrión-Nieves AI; Perez-Alcalá A; Pérez-García C; González-Juanatey C; Llorca J; Gonzalez-Gay MA;
RMD Open; 2024 Apr; 10(2):. PubMed ID: 38631846
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular outcomes in systemic sclerosis with abnormal cardiovascular MRI and serum cardiac biomarkers.
Dumitru RB; Bissell LA; Erhayiem B; Kidambi A; Dumitru AH; Fent G; Abignano G; Donica H; Burska A; Greenwood JP; Biglands J; Schlosshan D; Del Galdo F; Plein S; Buch MH
RMD Open; 2021 Oct; 7(3):. PubMed ID: 34663635
[TBL] [Abstract][Full Text] [Related]
14. Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus.
Sivakumaran J; Harvey P; Omar A; Tayer-Shifman O; Urowitz MB; Gladman DD; Anderson N; Su J; Touma Z
Lupus Sci Med; 2021 May; 8(1):. PubMed ID: 34045359
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular outcome in systemic sclerosis.
Voilliot D; Magne J; Dulgheru R; Kou S; Henri C; Caballero L; De Sousa C; Sprynger M; Andre B; Pierard LA; Lancellotti P
Acta Cardiol; 2015 Oct; 70(5):554-63. PubMed ID: 26567815
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular risk estimation with 5 different algorithms before and after 5 years of bDMARD treatment in rheumatoid arthritis.
Cacciapaglia F; Fornaro M; Venerito V; Perniola S; Urso L; Iannone F
Eur J Clin Invest; 2020 Dec; 50(12):e13343. PubMed ID: 32654116
[TBL] [Abstract][Full Text] [Related]
17. Subclinical Atherosclerosis in Systemic Sclerosis: Not Less Frequent Than Rheumatoid Arthritis and Not Detected With Cardiovascular Risk Indices.
Ozen G; Inanc N; Unal AU; Korkmaz F; Sunbul M; Ozmen M; Akar S; Deniz R; Donmez S; Pamuk ON; Atagunduz P; Tigen K; Direskeneli H
Arthritis Care Res (Hoboken); 2016 Oct; 68(10):1538-46. PubMed ID: 26866424
[TBL] [Abstract][Full Text] [Related]
18. Atherosclerotic plaques occur in absence of intima-media thickening in both systemic sclerosis and systemic lupus erythematosus: a duplexsonography study of carotid and femoral arteries and follow-up for cardiovascular events.
Frerix M; Stegbauer J; Kreuter A; Weiner SM
Arthritis Res Ther; 2014 Feb; 16(1):R54. PubMed ID: 24548804
[TBL] [Abstract][Full Text] [Related]
19. Predictive performance of a competing risk cardiovascular prediction tool CRISK compared to QRISK3 in older people and those with comorbidity: population cohort study.
Livingstone SJ; Guthrie B; Donnan PT; Thompson A; Morales DR
BMC Med; 2022 May; 20(1):152. PubMed ID: 35505353
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study.
Hippisley-Cox J; Coupland C; Brindle P
BMJ; 2017 May; 357():j2099. PubMed ID: 28536104
[No Abstract] [Full Text] [Related]
[Next] [New Search]
